Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries (OP: BNXTF ) 0.1285 -0.1467 (-53.31%) Streaming Delayed Price Updated: 9:30 AM EDT, Jun 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 104 Open 0.1285 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 0.2752 Today's Range 0.1285 - 0.1285 52wk Range 0.0020 - 0.5656 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps March 17, 2024 Via ACCESSWIRE BioMedNewsBreaks – BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: BNXTF) (FSE: BXT) Announces Highly Promising Results from ODF Cladribine PK Study March 14, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Performance YTD -67.86% -67.86% 1 Month -55.10% -55.10% 3 Month -71.17% -71.17% 6 Month -64.53% -64.53% 1 Year -65.08% -65.08% More News Read More BioNxt Reports Successful Results From ODF Cladribine PK Study March 12, 2024 Via ACCESSWIRE BioNxt Reports Successful Results From ODF Cladribine Toxicity Study February 07, 2024 Via ACCESSWIRE BioNxt Solutions Announces Closing of Third and Final Tranche of Non-Brokered Private Placement October 27, 2023 Via ACCESSWIRE BioNxt Receives Delivery of Premium Commercial Coating and Cutting Equipment for Commercial Manufacturing of Drug Delivery Products December 12, 2023 Via ACCESSWIRE BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis Treament November 20, 2023 Via ACCESSWIRE BioNxt Reports on New Cladrabine ODF Product Development and Commercialization Program November 15, 2023 Via ACCESSWIRE BioNxt Signs Definitive Agreement For 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for The Treatment of Multiple Sclerosis November 13, 2023 Via ACCESSWIRE BioNxt Signs LOI for Acquisition of IP and Co-Development of ODF Drug Reformulation for Neurodegenerative Disease August 02, 2023 Via ACCESSWIRE BioNxt Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson’s Disease May 15, 2023 Via ACCESSWIRE BioNxt Successfully Completes Pilot Study for Contract Development Customer May 09, 2023 Via ACCESSWIRE BioNxt Secures Contract to Develop and Manufacture ODF Product for International Pharmaceutical Company April 24, 2023 Via ACCESSWIRE BioNxt Acquires Commercial Coating and Cutting Equipment to Build Out European Commercial Manufacturing Capacity April 17, 2023 Via ACCESSWIRE BioNxt Solutions Acquires Novel Precision Drug Coating and Delivery Technology March 07, 2023 Via ACCESSWIRE BioNxt Signs Clinical Study Agreement and Commences Manufacture of Clinical Samples for Study of Transdermal Rotigotine Patch for Parkinson’s Disease March 01, 2023 Via ACCESSWIRE Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
